Monitoring the VEGF level in aqueous humor of patients with ophthalmologically relevant diseases via ultrahigh sensitive paper-based ELISA

Biomaterials

Volumn 35, Issue 12, 2014, Pages 3729-3735

  Hsu, Min Yen ^a,b   Yang, Chung Yao ^b   Hsu, Wen Hsin ^c   Lin, Keng Hung ^a   Wang, Chun Yuan ^a   Shen, Ying Cheng ^a   Chen, Yu Chen ^a   Chau, Siu Fung ^d   Tsai, Hin Yeung ^d   Cheng, Chao Min ^b,e  

^a Taichung General Veterans Hospital   (Taiwan)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^d Buddhist Tzu Chi General   (Taiwan)

^e INSTITUTE OF CELLULAR AND ORGANISMIC BIOLOGY   (Taiwan)

Author keywords

Diabetic disease; Diagnosis; Ophthalmology; Paper based ELISA; VEGF

Indexed keywords

AGE-RELATED MACULAR DEGENERATION; CLINICAL DIAGNOSIS; DIABETIC RETINOPATHY; DIAGNOSTIC APPROACH; ISCHEMIC CONDITIONS; PAPER-BASED ELISA; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF;

BODY FLUIDS; COLORIMETRIC ANALYSIS; ENDOTHELIAL CELLS; EYE PROTECTION; OPHTHALMOLOGY; PAPER;

DIAGNOSIS;

BEVACIZUMAB; VASCULOTROPIN;

AQUEOUS HUMOR; ARTICLE; COLORIMETRY; CONJUGATION; CONTROLLED STUDY; DIABETIC RETINOPATHY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE DISEASE; HUMAN; LABORATORY DEVICE; MAJOR CLINICAL STUDY; MONITORING; PAPER; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA VEIN OCCLUSION; SENILE CATARACT; SIGNAL PROCESSING; ULTRAHIGH SENSITIVE PAPER BASED ENZYME LINKED IMMUNOSORBENT ASSAY;

CELLS; COLORIMETRY; DIAGNOSIS; DISEASES;

DIABETIC DISEASE; DIAGNOSIS; OPHTHALMOLOGY; PAPER-BASED ELISA; VEGF;

AQUEOUS HUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE DISEASES; HUMANS; LIMIT OF DETECTION; PAPER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84893810956     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.01.030     Document Type: Article

References (31)

1. Adamis A.P., Miller J.W., Bernal M.T., D'Amico D.J., Folkman J., Yeo T.K., et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994, 118:445-450.
2. Shams N., Ianchulev T. Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol Clin North Am 2006, 19:335-344.
3. Wong T.Y., Scott I.U. Clinical practice. Retinal-vein occlusion. NEngl J Med 2010, 363:2135-2144.
4. Rosenfeld P.J., Brown D.M., Heier J.S., Boyer D.S., Kaiser P.K., Chung C.Y., et al. Ranibizumab for neovascular age-related macular degeneration. NEngl J Med 2006, 355:1419-1431.
5. Sawada O., Kawamura H., Kakinoki M., Sawada T., Ohji M. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol 2007, 125:1363-1366.
6. de Jong P.T. Age-related macular degeneration. NEngl J Med 2006, 355:1474-1485.
7. Funatsu H., Yamashita H., Noma H., Mimura T., Nakamura S., Sakata K., et al. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol 2005, 243:3-8.
8. Campochiaro P.A., Choy D.F., Do D.V., Hafiz G., Shah S.M., Nquyen Q.D., et al. Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology 2009, 116:2158-2164.
9. Sharma R.K., Rowe-Rendleman C.L. Validation of molecular and genomic biomarkers of retinal drug efficacy: use of ocular fluid sampling to evaluate VEGF. Neurochem Res 2011, 36:655-667.
10. Funatsu H., Yamashita H., Noma H., Mimura T., Tamashita T., Hori S. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 2002, 133:70-77.
11. Patel J.I., Hykin P.G., Schadt M., Luong V., Fitzke F., Gregor Z.J. Pars plana vitrectomy with and without peeling of the inner limiting membrane for diabetic macular edema. Retina 2006, 26:5-13.
12. Sharma R.K., Rogojina A.T., Chalam K.V. Multiplex immunoassay analysis of biomarkers in clinically accessible quantities of human aqueous humor. Mol Vis 2009, 15:60-69.
13. Cheng C.-M., Martinze A.W., Gong J., Mace C.R., Phillips S.T., Careilho E., et al. P-ELISA. Angew Chem Int Ed 2010, 49:4771-4774.
14. Mitchell P., Korobelnik J.F., Lanzetta P., Holz F.G., Prunte C., Schmidt-Erfurth U., et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010, 94:2-13.
15. Lo S.-J., Yang S.-C., Yao D.-J., Chen J.-H., Tu W.-C., Cheng C.-M. Molecular-level dengue fever diagnostic devices made out of paper. Lab Chip 2013, 13:2686-2692.
16. Wang H-K, Tsai C-C, Chen K-H, Tang C-T, Leou J-S, Li P-C, etal. Cellulose-based diagnostic devices for diagnosing serotype-2 dengue fever in human serum. Adv Healthc Mater. http://dx.doi.org/10.1002/adhm.201300150.
17. Martinez A.W., Phillips S.T., Carrilho E., Thomas S.W., Sindi H., Whitesides G.M. Simple telemedicine for developing regions camera phones and paper based microfluidic devices for real time, off site diagnosis. Anal Chem 2008, 80:3699-3707.
18. Pollock N.R., Rolland J.P., Kumar S., Beattie P.D., Jain S., Noubary F., et al. Apaper-based multiplexed transaminase test for low-cost, point-of-care liver function testing. Sci Trans Med 2012, 4:152ra129.
19. Wu H-Y, Rubinstein M, Shih E, Guttag J, Durand F, Freeman W. Eulerian video magnification for revealing subtle changes in the world. ACM T Graph;31:65.
20. Aouizerate F., Cazenave J., Poirier L., Verin P., Cheyrou A., Begueret J., et al. Detection of Toxoplasma gondii in aqueous humour by the polymerase chain reaction. Br J Ophthalmol 1993, 77:107-109.
21. Bou G., Fiqueroa M.S., Martí-Belda P., Navas E., Guerrero A. Value of PCR for detection of Toxoplasma gondii in aqueous humor and blood samples from immunocompetent patients with ocular toxoplasmosis. JClin Microbiol 1999, 37:3465-3468.
22. Tolentino M.J. Current molecular understanding and future treatment strategies for pathologic ocular neovascularization. Curr Mol Med 2009, 9:973-981.
23. Stewart M.W., Rosenfeld P.J., Penha F.M., Wang F., Yehoshua Z., Bueno-Lopez E., et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor trap-eye). Retina 2012, 32:434-457.
24. Krohne T.U., Eter N., Holz F.G., Meyer C.H. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008, 146:508-512.
25. Balaiya S., Grover S., Murthy R.K., Chalam K.V. Freezing adversely affects measurement of vascular endothelial growth factor levels in human aqueous samples. Clin Ophthalmol 2011, 5:81-85.
26. Folk J.C., Stone E.M. Ranibizumab therapy for neovascular age-related macular degeneration. NEngl J Med 2010, 363:1648-1655.
27. Mitchell P. Asystematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. Curr Med Res Opin 2011, 27:1465-1475.
28. Campbell R.J., Bell C.M., Campbell Ede L., Gill S.S. Systemic effects of intravitreal vascular endothelial growth factor inhibitors. Curr Opin Ophthalmol 2013, 24:197-204.
29. Mourits M.P., Prummel M.F., Wiersinga W.M., Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol 1997, 47:9-14.
30. Narváez J., Chakrabarty A., Chang K. Treatment of epithelial ingrowth after LASIK enhancement with a combined technique of mechanical debridement, flap suturing, and fibrin glue application. Cornea 2006, 25:1115-1117.
31. Zakaria N., Van Grasdorff S., Wouters K., Rozema J., Koppen C., Lion E., et al. Human tears reveal insights into corneal neovascularization. PLoS One 2012, 7:e36451.